Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Karlin, MD
Poniard Pharmaceuticals
Study Director - Hazel Breitz, MD
Poniard Pharmaceuticals
Study Director - Paul Weiden, MD
Poniard Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Cancer Center
Calgary, Alberta, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Facility name not stated
Ufa, Bashkortostan Republic, Russia
- Facility name not stated
Stepanovskoye, Krasnogorskiy District, Moscow Oblast, Russia
- Facility name not stated
Petrozavodsk, Republic of Karelia, Russia
- Facility name not stated
Engel's, Saratov Oblast, Russia
- Facility name not stated
Kazan', Tatarstan Republic, Russia
- Facility name not stated
Izhevsk, Udmurtiya Republic, Russia
- Facility name not stated
Cherepovets, Vologda Oblast, Russia
- Facility name not stated
Astrakhan, Russia
- Facility name not stated
Barnaul, Russia
- Facility name not stated
Chelyabinsk, Russia
- Facility name not stated
Kaliningrad, Russia
- Facility name not stated
Krasnodar, Russia
- Facility name not stated
Moscow, Russia
- Facility name not stated
Nizhny Novgorod, Russia
- Facility name not stated
Omsk, Russia
- Facility name not stated
Orenburg, Russia
- Facility name not stated
Pyatigorsk, Russia
- Facility name not stated
Rostov-on-Don, Russia
- Facility name not stated
Saint Petersburg, Russia
- Facility name not stated
Samara, Russia
- Facility name not stated
Stavropol, Russia
- Facility name not stated
Ulyanovsk, Russia
- Facility name not stated
Voronezh, Russia
- Facility name not stated
Yaroslavl, Russia
- Facility name not stated
Yekaterinburg, Russia
- Genesis Cancer Center
Hot Springs, Arkansas, United States
- Study Site
Los Angeles, California, United States
- Comprehensive Cancer Center
Palm Springs, California, United States
- Eastern Connecticut Hematology/oncology
Norwich, Connecticut, United States
- Oncology Hematology Group of South Florida
Miami, Florida, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- Augusta Oncology Associates
Augusta, Georgia, United States
- Central Georgia Hematology Oncology Associates
Macon, Georgia, United States
- Georgia Cancer Specialists
Tucker, Georgia, United States
- Rush Medical College
Chicago, Illinois, United States
- Medical Center of Vincennes
Vincennes, Indiana, United States
- University of Kansas Medical Center
Kansas City, Kansas, United States
- Markey Cancer Center, University of Kentucky
Lexington, Kentucky, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2005
- Primary completion
- 31 Mar 2007
- Completion
- 31 Mar 2008
- Last update posted
- 21 Jan 2009
- Registered enrollment
- 75
- Registry id
- NCT00116610
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.